Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis
Date
2022
Authors
Whittle, S.L.
Glennon, V.
Johnston, R.V.
Avery, J.C.
Bell, J.S.
Brennan, S.E.
Fong, C.
Hissaria, P.
Horgan, B.
O'Neill, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Internal Medicine Journal, 2022; 52(10):1799-1805
Statement of Responsibility
Samuel L. Whittle, Vanessa Glennon, Renea V. Johnston, Jodie C. Avery, J. Simon Bell, Sue E. Brennan, Christopher Fong, Pravin Hissaria, Ben Horgan, Sean O, Neill, Huai Leng Pisaniello, Lyndal Trevena, Glen A. Whittaker, Anita Wluka, and Rachelle Buchbinder
Conference Name
Abstract
Biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) have been an important advance in the management of inflammatory arthritis, but are expensive medications, carry a risk of infection and other adverse effects, and are often perceived as a burden by patients. We used GRADE methodology to develop recommendations for dose reduction and discontinuation of b/tsDMARDs in people with rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA) who have achieved a low disease activity state or remission. The recommendations form part of the Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis, an NHMRC-endorsed 'living' guideline, in which recommendations are updated in near real-time as new evidence emerges. Conditional recommendations were made in favour of dose reduction in RA and AxSpA but not in PsA. Abrupt discontinuation of b/tsDMARDs is not recommended in any of the three diseases.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2022 Royal Australasian College of Physicians.